Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1831 - Circulating Tumor DNA Detection in Primary Breast Cancer Patients by Targeted Sequencing:Consistency with Tumor DNA and Factors Influencing Detection (83P)


18 Nov 2017


Poster lunch


Translational Research;  Breast Cancer


Zhou Yidong


Annals of Oncology (2017) 28 (suppl_10): x16-x24. 10.1093/annonc/mdx655


Z. Yidong1, W. Changjun1, Z. Yanyan2, G. Yuhua2, G. Yanfang2, P. Li1, Y. Ling2, Y. Xin2, X. Xuefeng3, S. Qiang1

Author affiliations

  • 1 Department Of Breast Surgery, Peking Union Medical College Hospital, 100730 - BeiJing/CN
  • 2 Research And Development Center, Geneplus-Beijing Institute, 102206 - BeiJing/CN
  • 3 Center For Diabetes Research, The Methodist Hospital Research Institute, Houston/AS


Abstract 1831


Breast cancer is the most frequently diagnosed cancer worldwide in females with high mortality. As a noninvasive means to monitor the tumor genomes, circulating tumor DNA(ctDNA) detection has been applied to predict relapse and prognosis. However, systematic evaluation of ctDNA detection in plasma from patients with primary breast cancer(PBC) has not been performed. The aim of the study is to comprehensively assess the ctDNA detection and explore the factors affecting the release of ctDNA in patients with PBC.


71 females (8 stage I, 18 stage II, 38 stage III, 7 stage IV) with PBC newly diagnosed in Peking Union Medical College Hospital were selected in 2016. We analyzed genomic alterations of tumor tissues and matched plasma samples before the patients accepted any treatment by targeted sequencing in 1,021 cancer-associated genes.


Of the 71 patients, 273 somatic mutations were detected in 71 tumor tissues, and 122 somatic mutations were detected in 49 plasmas; consistent mutations were observed in 44 patients. The concordance rate of plasma with tumor tissue was 61.97% and detection rate of it was 69.01%. 21 mutations including BRAF, GNAS, PTEN, were observed only in plasmas but not in tumor tissues. Consistent mutations were mainly TP53 and PIK3CA. The ctDNA detection rate was ly associated with tumor size (P=0.03) and lymph node metastasis or not(P=0.005), while it showed no significant differences with various age groups, HR status, Her2 amplification status, Ki67 levels and clinical pathological subtypes.


The study provided evidence that ctDNA detection was a complementary approach for patients with PBC. It implied the PBC patients with larger tumor or lymph node metastasis were more likely to benefit from ctDNA detection.

Clinical trial identification

Legal entity responsible for the study

Peking Union Medical College Hospital




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.